Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo

Angiogenesis

Volumn 6, Issue 2, 2003, Pages 121-128

  Toi, Masakazu ^a   Bando, Hiroko ^a   Ramachandran, Cheppail ^b   Melnick, Steven J ^b   Imai, Atsushi ^c   Fife, Rose S ^d   Carr, Raymond Eric ^d   Oikawa, Tsutomu ^e   Lansky, Ephraim Philip ^f  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b MIAMI CHILDREN'S HOSPITAL   (United States)

^c GIFU UNIVERSITY   (Japan)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^f Rimonest Ltd   (Israel)

Author keywords

Angiogenesis; Breast cancer; Chemoprevention; MIF; Punica granatum; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; INTERLEUKIN 4; MIGRATION INHIBITION FACTOR; POLYPHENOL DERIVATIVE; POMEGRANATE EXTRACT; POMEGRANATE SEED OIL; UNCLASSIFIED DRUG; VASCULOTROPIN;

AMNION FLUID; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER INVASION; CELL PROLIFERATION; CHICKEN; CHORIOALLANTOIS; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; MYOMETRIUM; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION;

ANGIOGENESIS INHIBITORS; CELLS, CULTURED; DOWN-REGULATION; ENDOTHELIUM, VASCULAR; FIBROBLASTS; HUMANS; INTERLEUKIN-4; NEOVASCULARIZATION, PATHOLOGIC; PLANT EXTRACTS; PUNICACEAE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

GALLUS GALLUS; LYTHRACEAE; MINK CELL FOCUS-FORMING VIRUS; PUNICA GRANATUM;

EID: 0842333242     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:AGEN.0000011802.81320.e4     Document Type: Article

References (38)

1. Eatock MM, Schatzlein A, Kaye SB. Tumour vasculature as a target for anticancer therapy. Cancer Treat Rev 2000; 26: 191-204.
2. Pfeffer U, Ferrari N, Morini M et al. Antiangiogenic activity of chemopreventive drugs. Int J Biol Markers 2003; 18: 70-4.
3. Scappaticci FA. The therapeutic potential of novel antiangiogenic therapies. Expert Opin Invest Drugs 2003; 12: 923-32.
4. Auerbach R, Lewis R, Shinners B et al. Angiogenesis assays: A critical overview. Clin Chem 2003; 49: 32-40.
5. Kim ND, Mehta R, Yu W et al. Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res Treat 2002; 71: 203-17.
6. Fotsis T, Pepper MS, Montesano R et al. Phytoestrogens and inhibition of angiogenesis. Baillieres Clin Endocrinol Metab 1998; 12: 649-66.
7. Le Marchand L. Cancer preventive effects of flavonoids - a review. Biomed Pharmacother 2002; 56: 296-301.
8. Sartippour MR, Heber D, Zhang L et al. Inhibition of fibroblast growth factors by green tea. Int J Oncol 2002; 21: 487-91.
9. Schubert SY, Lansky EP, Neeman I. Antioxidant and eicosanoid enzyme inhibition properties of pomegranate seed oil and fermented juice flavonoids. J Ethnopharmacol 1999; 66: 11-7.
10. Masso-Welch PA, Zangani D, Ip C et al. Inhibition of angiogenesis by the cancer chemopreventive agent conjugated linoleic acid. Cancer Res 2002; 62: 4383-9.
11. Kunz-Schughart LA, Knuechel R. Tumor-associated fibroblasts (part I): Active stromal participants in tumor development and progression? Histol Histopathol 2002; 17: 599-621.
12. Hartlapp I, Abe R, Saeed RW et al. Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. FASEB J 2001; 15: 2215-24.
13. Kapiteijn K, Koolwijk P, Van Der Weiden R et al. Steroids and cytokines in endometrial angiogenesis. Anticancer Res 2001; 21: 4231-42.
14. Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: Its prognostic, predictive, and therapeutic implications. Lancet Oncol 2001; 2: 667-73.
15. Nagai S, Toi M. Interleukin-4 and breast cancer. Breast Cancer 2000; 7: 181-6.
16. Bando H, Matsumoto G, Bando M et al. Expression of macrophage migration inhibitory factor in human breast cancer: Association with nodal spread. Jpn J Cancer Res 2002; 93: 389-96.
17. Imamura M. Extracellular matrix components and angiogenesis. Nippon Yakurigaku Zasshi 1996; 107: 153-60.
18. Ueno T, Toi M, Saji H et al. The role of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis and survival of human breast cancer. Clin Cancer Res 2000; 6: 3282-9.
19. Oikawa T, Sasaki T, Nakamur M et al. The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 1998; 246: 243-8.
20. Fife RS, Sledge Jr GW, Sissons S et al. Effects of tetracyclines on angiogenesis in vitro. Cancer Lett 2000; 153: 75-8.
21. Oikawa T, Hirotani K, Nakamura O et al. A highly potent antiangiogenic activity of retinoids. Cancer Lett 1989; 48: 157-62.
22. Oikawa T, Hirotani K, Ogasawara H et al. Inhibition of angiogenesis by vitamin D3 analogues. Eur J Pharmacol 1990; 178: 247-50.
23. Nakamura M, Katsuki Y, Shibutani Y, Oikawa T. Dienogest, a synthetic steroid, suppresses both embryonic and tumor-cell-induced angiogenesis. Eur J Pharmacol 1999; 386: 33-40.
24. Pavlakovic H, Havers W, Schweigerer L. Multiple angiogenesis stimulators in a single malignancy: Implications for anti-angiogenic tumour therapy. Angiogenesis 2001; 4: 259-62.
25. Maulik N, Das D. Redox signaling in vascular angiogenesis (1,2). Free Radic Biol Med 2002; 33: 1047.
26. Leek RD, Talks KL, Pezzella F et al. Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in human breast cancer. Cancer Res 2002; 62: 1326-9.
27. Sasaki H, Ray PS, Zhu L et al. Oxidative stress due to hypoxia/ reoxygenation induces angiogenic factor VEGF in adult rat myocardium: Possible role of NFkappaB. Toxicology 2000; 155: 27-35.
28. Schubert SY, Neeman I, Resnick N. A novel mechanism for the inhibition of NFkB activation in vascular endothelial cells by natural antioxidants. FASEB J 2002; 16: 1931-3.
29. Sharaf A, Nigm SAR. The oestrogenic activity of pomegranate seed oil. J Endocrinol 1964; 29: 91-2.
30. Cid MC, Schnaper HW, Kleinman HK. Estrogens and the vascular endothelium. Ann N Y Acad Sci 2002; 966: 143-57.
31. Gargett CE, Zaitseva M, Bucak K et al. 17Beta-estradiol up-regulates vascular endothelial growth factor receptor-2 expression in human myometrial microvascular endothelial cells: Role of estrogen receptor-alpha and -beta. J Clin Endocrinol Metab 2002; 87: 4341-9.
32. Galea E, Santizo R, Feinstein DL et al. Estrogen inhibits NF kappa B-dependent inflammation in brain endothelium without interfering with 1 kappa B degradation. Neuroreport 2002; 13: 1469-72.
33. White RE. Estrogen and vascular function. Vasc Pharmacol 2002; 38: 73-80.
34. Takei H, Lee ES, Jordan VC. In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer. Breast Cancer 2002; 9: 39-42.
35. Nugteren DH, Christ-Hazelhof E. Naturally occurring conjugated octadecatrienoic acids are strong inhibitors of prostaglandin biosynthesis. Prostaglandins 1987; 33: 403-17.
36. Fukuda R, Kelly B, Semenza GL. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res 2003; 63: 2330-4.
37. Meyer-Siegler K. COX-2 specific inhibitor, NS-398, increases macrophage migration inhibitory factor expression and induces neuroendocrine differentiation in C4-2b prostate cancer cells. Mol Med 2001; 7: 850-60.
38. Lansky EP, Jiang WG, Mo H et al. Therapeutic synergy in pomegranate. Poster presented at the 94th Annual Meeting of the American Association for Cancer Research, July 11-14, 2003, Washington, DC.